Treatment of hepatitis C in dialysis patients

Contributions to Nephrology

Volumn 176, Issue , 2012, Pages 54-65

  Esforzado, Nuria ^a,b   Campistol, Josep Maria ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN;

ARTICLE; CHRONIC KIDNEY FAILURE; GENETICS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER TRANSPLANTATION; RENAL REPLACEMENT THERAPY; VIROLOGY;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; KIDNEY FAILURE, CHRONIC; LIVER TRANSPLANTATION; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RENAL DIALYSIS; RIBAVIRIN;

EID: 84856888334     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000332383     Document Type: Article

References (31)

1. Jadoul M, Poignet JL, Geddes C, Locatelli F, Medin C, Krajewska M, Barril G, Scheuermann E, Sonkodi S, Goubau P HCV Collaborative Group: The changing epidemi-ology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant 2004;19:904-909. (Pubitemid 38455663)
2. Seeff LB: Natural history of chronic hepatitis C. Hepatology 2002;36:S35-S46. (Pubitemid 35253462)
3. Fabrizi F, Takkouche B, Lunghi G, Dixit V MessaP, Martin P: The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational stud-ies. J Viral Hepat 2007;14:697-703. (Pubitemid 47414935)
4. Fenning L, Kenny E, Sheehan M, Cannon B, Whelton M, O'Conneh J, Collins JK, Shanahan F: Viral load and clinicopathologi-cal features of chronic hepatitis C (1b) in a homogeneus patient population. Hepatology 1999;29:904-907. (Pubitemid 29109608)
5. Zylberberg H, Nalpas B, Carnot F, Skhiri H, Fontaine H, Legendre C, Kreis H, Bréchot C, Pol S: Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant 2002;17:129-133. (Pubitemid 34093022)
6. TenCate V, Sainz Jr B, Cotler SJ, Uprichard SL: Potential treatment options and future research to increase hepatitis C virus treat-ment response rate. Hepat Med 2010;2:125-145.
7. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB: Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treat-ment efficacy and harms. Am J Kidney Dis 2008;51:263-277.
8. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB: Interferon for hepatitis C virus in hemodialysis -an individual patient meta-analysis of factors associated with sustained virological response. Clin J Am Soc Nephrol 2009;4:1449-1458.
9. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P: Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003;18:1071-1081. (Pubitemid 38021592)
10. Russo M W, Goldsweig CD, Jacobson IM, Brown RS Jr: Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003;98:1610-1615. (Pubitemid 36875356)
11. Fabrizi F Dixit V, Messa P, Martin P: Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clini-cal trials. J Viral Hepat 2008;15:79-88.
12. Rostaing L, Chatelut E, Payen JL, Izopet J, Thalamas C, Ton-That H, Pascal JP, Durand D, Canal P: Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998;9:2344-2348. (Pubitemid 28543813)
13. Liu CH, Liang CC, Lin JW, Chen SI, Tsai HB, Chang CS, Hung PH, Kao JH, Liu CJ, Lai MY, Chen JH, Chen PJ, Kao JH, Chen DS: Pegylated interferon alpha-2a versus stan-dard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut 2008;57:525-530.
14. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672.
15. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER Goodman ZD, Laughlin M, Yao R, Albrecht JK, Hepatitis Interventional Therapy Group: A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepa-titis C. Hepatology 2001;34:395-403. (Pubitemid 32702353)
16. Gupta SK, Pittenger AL, Swan SK, Marbury TC, Tobillo E, Batra V, Sack M, Glue P, Jacobs S, Affrime M: Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol 2002;42:1109-1115.
17. Fabrizi F, Dixit V, Messa P, Martin P: Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Med Virol 2010;82:768-775.
18. Brochot E, Castelain J, Duverlie G, Capron D, Nguyen-Khac E, François C: Ribavirin monitoring in chronic hepatitis C therapy: anemia versus efficacy Antiviral Ther 2010;15:687-695.
19. Bruchfeld A, Stahle L, Andersson J, Schvarcz R: Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection -a pilot study. J Viral Hepat 2001;8:287-292. (Pubitemid 32673741)
20. Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA: Alpha-interferon with ribavirin in the treat-ment of hemodialysis patients with hepatitis C. Transplant Proc 2004;36:1831-1834. (Pubitemid 39200440)
21. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R: Pegylated inter-feron and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006;13:316-321.
22. Rendina M, Schena A, Castellaneta NM, Losito F, Amoruso AC, Stallone G, Schena FP, Di Leo A, Francavilla A: The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007;46:768-774. (Pubitemid 46529043)
23. Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT: Treatment of dialysis patients with chronic hepatitis C using pegy-lated interferon and low-dose ribavirin. Int J Artif Organs 2008;31:295-302. (Pubitemid 351890659)
24. Van Leusen R, Adang RP, de Vries RA, Cnossen TT, Konings CJ, Schalm SW, Tan AC: Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2008;23:721-725. (Pubitemid 351767641)
25. Hakim W, Sheikh S, Inayat I, Caldwell C, Smith D, Lorber M, Friedman A, Jain D, Bia M, Formica R, Mehal W: HCV response in patients with end stage renal disease treated with combination pegylated interferon alpha-2a and ribavirin. J Clin Gastroenterol 2009;43:477-481.
26. Liu CH, Liang CC, Liu CJ, Tsai HB, Hung PH, Hsu SJ, Chen SI, Lin JW, Lai MY Chen JH, Chen PJ, Chen DS, Kao JH: Pegylated interferon alfa-2a plus low dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior inter-feron monotherapy Gut 2009;58:314-316.
27. Liu CH, Kao JH: Treatment of hepatitis C virus infection in patients with end-stage renal disease. J Gastroenterol Hepatol 2011;26:228-239.
28. Liu CH, Liang CC, Liu CJ, Lin JW, Chen SI, Hung PH, Tsai HB, Lai MY, Chen PJ, Chen DS, Kao JH: Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C. Clin Infect Dis 2010;51:541-549.
29. Kidney Disease: Improving Global Outcomes (KDIGO): KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008;109:S1-S99.
30. Ghany MG, Strader B, Thomas DL, Seeff LB: Diagnosis, management and treat-ment of hepatitis C: an update. Hepatology 2009;49:1335-1374.
31. Sulkowski CMS, Cooper C, Hunyady B, Jia J, Ogurtsov P Peck-Radosavljevic M, Shiffman ML, Yurdaydin C, Dalgard O: Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroeneterol Hepatol 2011;8:212-223.